The treatments today are as ineffective as they will ever be, looking ahead: Weight loss efficacy is increasing from 15% to 20% to 25% to 30% The label is expanding from Diabetes to Obesity to Heart Disease and likely Kidney Disease and Sleep Apnea
Since researchers used data from Medicare administrative claims, it is possible that they missed some health information or that there was misclassification, such as misclassification of depression cases
Weight loss with Semaglutide GLP-1 varies depending on individual factors such as dosage, adherence to lifestyle changes, and overall health
Hansen AL, Dahl L, Olson G, Thornton D, Graff IE, Fryland L, et al
In preclinical studies, GIP and GLP1 reduce atherosclerosis